No internet connection — showing the saved version of the page.

武田薬品工業

Takeda Pharmaceutical Co Ltd ADRUSUSD
← to the screener

Takeda Pharmaceutical Co Ltd ADR (US:TKPHF) — Biotechnology: Pharmaceutical Preparations. Number of exchanges where the company shares trade: 3. On this page — price and chart, dividends, top holders and share count history.

About the company

Website
takeda.co.jp
Sector
Health Care · Biotechnology: Pharmaceutical Preparations
Headquarters
TOKYO, Japan
CEO
Julie Kim
Employees
47 029
Founded
1781
Shares outstanding
1.6 B as of 2026-10-16
DateSharesChange
16.10.20261.6 B—no significant change
15.10.20261.6 B—no significant change
14.10.20261.6 B—no significant change
13.10.20261.6 B—no significant change
09.10.20261.6 B—no significant change
08.10.20261.6 B—no significant change
07.10.20261.6 B
Share count from the company reports. A split is detected by a jump in the count by a whole number of times.
Free float
3.16 B
Market cap
9.94 T JPY
Insiders
0.07%
Institutions
3.31%
Industry (SIC)
Pharmaceutical Preparations
Legal form
T417
ISIN
US8740602052
LEI
549300ZLMVP4X0OGR454
Payout ratio
loss
FCF
627 B JPY
Payout / FCF
49%
Debt
4.94 T JPY
7.1 y of FCF
Dividend streak
—
Earnings, FCF and dividends paid — for the 12 months to 30.06.2026 (the company's latest report).
Description

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, oncology, vaccines, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Takhzyro, Advate, Elaprase, Replagal, Vpriv, Adynovate/Adynovi, Livtencity, ADZYNMA, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Flexbumin, Adcetris, Leuplin/Enantone, Ninlaro, Iclusig, FRUZAQLA, Alunbrig, vyvanse/elvanse, Trintellix, and QDENGA brands. It has licensing and collaboration for the development and commercialization of products with Arrowhead Pharmaceuticals, Cour Pharmaceuticals, Engitix, Halozyme, Mirum Pharmaceuticals, Ucsd/Fortis Advisors, Zedira/Dr. Falk Pharma, Ac Immune, Acurastem, Anima Biotech, Biomarin, Denali Therapeutics, Luxna Biotech, Neurocrine Biosciences, Peptidream, Abbvie, Adimab, Ascentage Pharma, Crescendo Biologics, Exelixis, F-Star, Gsk, Heidelberg Pharma, Innovent Biologics, Keros Therapeutics, Kumquat Biosciences, Protagonist Therapeutics, Halozyme, Kamada, Johnson & Johnson/Momenta Pharmaceuticals, Previpharma, Novavax, Bridgene Biosciences, Charles River Laboratories, Iambic Therapeutics, Ipsen, Km Biologics, Massachusetts Institute Of Technology, and Nabla Bio. The company operates in Japan, the United States. Europe, Canada, Latin America, China, Asia, Russia/Commonwealth of Independent States, the Middle East, Oceania, and Africa. The company was founded in 1781 and is headquartered in Chuo, Japan.

advertisement

Exchanges and tickers

ExchangeTickerCurrencyPriceType
US USA StocksTKPHF OTCUSD38.635 +14.14%common stock
TSE Tokyo Stock Exchange4502 primaryJPY6 223 +0.65%common stock
VI Vienna Stock ExchangeTKD secondaryEUR33.01 +1.29%common stock

Price for 3 months

up day down day dividend ex-date payment dateHover / tap a day — open, close, high and low prices

Dividends

Per year, US:TKPHF: 202 JPY (2 paym.)

Takeda Pharmaceutical Co Ltd ADR (TKPHF) pays dividends twice a year. Per year (12 months up to and including the latest announced payment): 202 JPY per share (payments: 2). Based on payment history, the next ex-dividend date is expected around 31.03.2027.

Ex-datePaymentAmount%TypeTicker
2026-09-30—102.0000 JPY1.7/3.4 %semi-annualUS:TKPHF
2026-03-312026-06-25100.0000 JPY1.8/3.7 %semi-annualUS:TKPHF
2025-09-302025-12-01100.0000 JPY2.2/4.3 %semi-annualUS:TKPHF
2025-03-312025-06-2698.0000 JPY2.0/3.9 %semi-annualUS:TKPHF
2024-09-302024-12-0298.0000 JPY2.4/≈4.7 %semi-annualUS:TKPHF
2024-03-282024-06-2794.0000 JPY2.1/≈4.3 %semi-annualUS:TKPHF

Top holders

HolderStakeSharesReport date
Capital Research Global…0.6%19.3 M2026-06-30
AMERICAN MUTUAL FUND0.57%18.16 M2026-06-30
FMR, LLC0.3%9.6 M2026-06-30
Morgan Stanley0.22%6.99 M2026-06-30
Adage Capital Partners G…0.19%6.05 M2026-06-30
Goldman Sachs Group Inc0.16%5.13 M2026-06-30
Brandes Investment Partn…0.14%4.54 M2026-06-30
Arrowstreet Capital, Lim…0.12%3.73 M2026-06-30
Blackrock Inc.0.12%3.69 M2026-06-30
Renaissance Technologies…0.08%2.57 M2026-06-30
Qube Research & Technolo…0.07%2.21 M2026-06-30
First TRT Exch-Trd Fd.-F…0.06%1.88 M2026-08-31
VanEck ETF Trust-VanEck…0.06%1.79 M2026-08-31
Steward Funds Inc-Stewar…0.02%711 8712026-04-30
Mercer Funds-Mercer Non-…0.02%586 0982026-06-30
American Century ETF Tru…0.02%553 0082026-08-31
GOLDMAN SACHS TRUST-Gold…0.02%494 4422026-07-31
WEBER CHRISTOPHE PIERRE…≈0.01%418 8032026-04-27
KIM JULIE SO-YOUNG (Chie…≈0.01%391 4892026-08-10
Trust for Professional M…0.01%170 1132026-05-31
MUTUAL FUND SERIES TRUST…0.01%169 0002026-06-30
PLATFORD GILES RICHARD (…≈0.01%315 8382026-08-10
BITETTI TERESA MARIE (Of…≈0.01%252 0102026-08-10
FURNEY NATALIE ANNE MARI…≈0.01%204 2982026-08-10
DUPREY LAUREN RUSCKOWSKI…≈0.01%191 5222026-09-14
PACHECO RHONDA JANICE (O…≈0.01%182 5072026-08-10
PIGNAGNOLI AGOSTI MARCEL…≈0.01%176 9772026-08-10
RICCI GABRIELE (Chief Te…≈0.01%171 6542026-08-10
Carillon Series Trust-Ca…0%160 0002026-06-30
PLUMP ANDREW STEWART (Of…——2026-09-02